ArticleCurrent atherosclerosis reports2014
Noncoding RNAs and atherosclerosis.
Article in Current atherosclerosis reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 93 citations in OpenAlex.
- Plasma Circulating Extracellular RNAs in Left Ventricular Remodeling Post-Myocardial Infarction.EBioMedicine · 2018Trial
- Integrated analysis of long noncoding RNA and mRNA profiling ox-LDL-induced endothelial dysfunction after atorvastatin administration.Medicine · 2018Trial
- Macrophage-associated noncoding RNAs in atherosclerosis and chronic kidney disease.Frontiers in cardiovascular medicine · 2026Review
- Epigenetic‑ncRNA crosstalk in atherosclerosis: Mechanisms, disease progression and therapeutic potential (Review).International journal of molecular medicine · 2025Review
- The Role of Selected lncRNAs in Lipid Metabolism and Cardiovascular Disease Risk.International journal of molecular sciences · 2024Review
- Role of long noncoding RNAs in diabetes-associated peripheral arterial disease.Cardiovascular diabetology · 2024Review
- NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies.Frontiers in pharmacology · 2024Review
- The Link between miRNAs and PCKS9 in Atherosclerosis.Current medicinal chemistry · 2024Review
- Novel Therapeutic Approaches to Prevent Atherothrombotic Ischemic Stroke in Patients with Carotid Atherosclerosis.International journal of molecular sciences · 2023Review
- A review on the biological roles of LncRNA PTCSC3 in cancerous and non-cancerous disorders.Cancer cell international · 2023Review
- Epigenetic mechanisms of particulate matter exposure: air pollution and hazards on human health.Frontiers in genetics · 2023Review
- Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis.International journal of molecular sciences · 2022Review
- CHOP Increases TRIB3-Dependent miR-208 Expression to Potentiate Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating TIMP3 in Atherosclerosis.Cardiovascular drugs and therapy · 2022Article
- Decoding microRNA drivers in atherosclerosis.Bioscience reports · 2022Review
- Article
- Article
- The correlation of long non-coding RNAs IFNG-AS1 and ZEB2-AS1 with IFN-γ and ZEB-2 expression in PBMCs and clinical features of patients with coronary artery disease.Molecular biology reports · 2022Article
- Study on effects of miR-141-3p in proliferation, migration, invasion and apoptosis of colon cancer cells by inhibiting Bcl2.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- CAD increases the long noncoding RNAMolecular therapy. Nucleic acids · 2021Article
- Role of long non-coding RNAs in adipogenesis: State of the art and implications in obesity and obesity-associated diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Noncoding RNAs (ncRNAs) represent a class of RNA molecules that typically do not code for proteins. Emerging data suggest that ncRNAs play an important role in several physiological and pathological conditions such as cancer and cardiovascular diseases, including atherosclerosis. The best-characterized ncRNAs are the microRNAs which are small, approximately 22-nucleotide sequences of RNA that regulate gene expression at the posttranscriptional level through transcript degradation or translational repression. MicroRNAs control several aspects of atherosclerosis, including endothelial cell, vascular smooth cell, and macrophage functions as well as lipoprotein metabolism. Apart from microRNAs, recently ncRNAs, especially long ncRNAs, have emerged as important potential regulators of the progression of atherosclerosis. However, the molecular mechanism of their regulation and function as well as the significance of other ncRNAs such as small nucleolar RNAs during atherogenesis is largely unknown. In this review, we summarize the recent findings in the field, highlighting the importance of ncRNAs in atherosclerosis and discuss their potential use as therapeutic targets in cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.